Nov. 10, 2022 Price forecast | 2 weeks: -0.43% | 1 month: -1.37% | 3 months: 23.34% | Premium Forecast

OCUL stock forecast

Our latest prediction for Ocular Therapeutix Inc's stock price was made on the Nov. 10, 2022 when the stock price was at 3.03$.

In the short term (2weeks), OCUL's stock price should underperform the market by -0.43%. During that period the price should oscillate between -11.26% and +8.44%.

In the medium term (3months), OCUL's stock price should outperform the market by 23.34%. During that period the price should oscillate between -33.15% and +43.99%.

Create a solid portfolio with OCUL

Add OCUL to your portfolio and optimize it!

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSureĀ® Sealant is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

At the moment the company generates 35M USD in revenues.

On its last earning announcement, the company reported a loss of -0.76$ per share.

The book value per share is 1.18$

Ocular Therapeutix Inc website

Three months stock forecastNov. 10, 2022


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
35M -20.71% -77M -216.30% -25M -0.76 - - 77M 1.18 - - -